{
  "abstract": "BACKGROUND: Migraine, particularly in its chronic and treatment-resistant forms, imposes a significant burden on patients. Monoclonal antibodies targeting the calcitonin gene-related peptide (CGRP) pathway (anti-CGRP mAbs) and onabotulinum toxin type A (BTX-A) have emerged as key preventive treatments for resistant migraine. However, direct comparisons between these therapies remain limited. OBJECTIVES: This study aimed to compare the effectiveness of anti-CGRP mAbs and BTX-A in patients with resistant migraine in a real-world setting at a single tertiary care center in France. METHODS: A retrospective cohort study was conducted, including 93 patients treated with either anti-CGRP mAbs (n=50) or BTX-A (n=43) for six months. Propensity score matching and inverse probability of treatment weighting (IPTW) were applied to balance baseline differences between groups. The primary outcome was the proportion of patients achieving a ≥50% reduction in monthly headache days. RESULTS: After six months, 43% of patients in the anti-CGRP mAbs group and 18% in the BTX-A group achieved a ≥50% reduction in monthly headache days (P=0.003). Using a less stringent 30% threshold, response rates were 54% for anti-CGRP mAbs and 36% for BTX-A (P=0.06). Similar results were observed when the analysis was restricted to chronic migraine patients (n=79). The reduction in monthly headache days was significantly greater in the anti-CGRP mAbs group at both three months (P=0.015) and six months (P=0.022). CONCLUSION: Anti-CGRP mAbs demonstrated superior efficacy compared to BTX-A in resistant migraine patients.",
  "abstract_shown": true,
  "affiliations": [],
  "article_type": null,
  "arxiv": null,
  "author_total": 9,
  "authors": [
    {
      "name": "L. Gardon"
    },
    {
      "name": "D. Guy"
    },
    {
      "name": "B. Pereira"
    },
    {
      "name": "S. Sickout-Arondo"
    },
    {
      "name": "C. Mongaret"
    },
    {
      "name": "N. Delage"
    },
    {
      "name": "P. Picard"
    },
    {
      "name": "S. Condé"
    },
    {
      "name": "Xavier Moisset"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/6ersb7nhknv8c.bib",
  "cited_by": 0,
  "doi": "10.1016/j.neurol.2025.10.006",
  "fulltext_url": null,
  "id": "6ersb7nhknv8c",
  "issns": [
    "0035-3787"
  ],
  "landing_url": "https://hal.science/hal-05794378v1",
  "language": "en",
  "licence": "CC-BY",
  "licence_label": "CC BY",
  "licence_source": "journal",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "hal",
      "0.sdv"
    ],
    [
      "hal",
      "1.sdv.neu"
    ],
    [
      "openalex",
      "2738|Migraine and Headache Studies"
    ]
  ],
  "openalex": "W4417232086",
  "pdf_url": null,
  "pmcid": null,
  "pmid": null,
  "published": "2026-10-12",
  "publisher": "Elsevier Masson",
  "ris": "https://research.draconitic.com/paper/6ersb7nhknv8c.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:17:54Z",
      "native_id": "hal-05794378",
      "source": "hal",
      "url": "https://hal.science/hal-05794378v1"
    }
  ],
  "subjects": [
    {
      "field": "biology",
      "origin": "hal:1.sdv.neu",
      "subfield": "neuroscience"
    }
  ],
  "title": "Real-world comparison of treatments with antibodies targeting the CGRP pathway or botulinum toxin type A for resistant migraine",
  "title_text": "Real-world comparison of treatments with antibodies targeting the CGRP pathway or botulinum toxin type A for resistant migraine",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:17:54Z",
  "url": "https://research.draconitic.com/paper/6ersb7nhknv8c",
  "venue": "Revue Neurologique",
  "versions": []
}